Maynard Um
-
-
-
-
-
-
-
Stifel on Neumora Therapeutics (NMRA): 'lack conviction' in Kora mechanism, but risk/reward 'highly upside biased'
-
-
-
-
-
-
-
RBC Capital Upgrades Neumora Therapeutics (NMRA) to Outperform
-
-
-
-
-
-
-
Stifel on Neumora Therapeutics (NMRA): ' it's hard to have much conviction in the mechanism in MDD'
-
-
-
-
-
-
-
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
-
-
-
-
-
-
-
BofA Securities Downgrades Neumora Therapeutics (NMRA) to Underperform
-
-
-
-
-
-
-
NMRA DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fi
-
-
-
-
-
-
-
ROSEN, A LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NMRA
-
415,810 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

